Nanoviricides (NNVC) Accounts Payables (2011 - 2026)
Nanoviricides' (NNVC) quarterly Accounts Payables came in at $905000.0 in Q1 2026, up 11.25% year-over-year from $813477.0 in Q1 2025, and down 2.61% quarter-over-quarter from $929232.0 in Q4 2025.
Powered by 
Analysis
Nanoviricides (NNVC) Accounts Payables (2011 - 2026) Analysis & Trends
Nanoviricides has disclosed Accounts Payables across 16 years of filings, most recently posting $905000.0 for Q1 2026.
- In Q1 2026, Accounts Payables rose 11.25% year-over-year to $905000.0; the TTM figure through Mar 2026 stood at $905000.0 (up 11.25% YoY), while the FY2025 annual figure was $821456.0, up 14.08% from the prior year.
- Accounts Payables came in at $905000.0 for Q1 2026 at Nanoviricides, down from $929232.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $929232.0 in Q4 2025 to a low of $37690.0 in Q3 2022.
- Average Accounts Payables over 5 years is $575088.8, with a median of $733434.0 recorded in 2023.
- Year-over-year, Accounts Payables tumbled 74.35% in 2022 and soared 2233.47% in 2023.
- Over 5 years, Accounts Payables stood at $39291.0 in 2022, then jumped by 2015.57% to $831227.0 in 2023, then climbed by 4.3% to $867000.0 in 2024, then increased by 7.18% to $929232.0 in 2025, then decreased by 2.61% to $905000.0 in 2026.
- Per Business Quant data, the three most recent Accounts Payables figures were $905000.0 in Q1 2026, $929232.0 in Q4 2025, and $901143.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 2.87 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 674.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 429.50 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.16 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 167.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 403.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 25.08 Mn |
| 10 | Nanoviricides | 22.04 Mn | 18.83 Mn | - | 905,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 905,000.00 |
| Dec 31, 2025 | 929,232.00 |
| Sep 30, 2025 | 901,143.00 |
| Jun 30, 2025 | 821,456.00 |
| Mar 31, 2025 | 813,477.00 |
| Dec 31, 2024 | 867,000.00 |
| Sep 30, 2024 | 713,000.00 |
| Jun 30, 2024 | 720,039.00 |
| Mar 31, 2024 | 341,394.00 |
| Dec 31, 2023 | 831,227.00 |
| Sep 30, 2023 | 879,485.00 |
| Jun 30, 2023 | 733,434.00 |
| Mar 31, 2023 | 62,695.00 |
| Dec 31, 2022 | 39,291.00 |
| Sep 30, 2022 | 37,690.00 |
| Jun 30, 2022 | 57,960.00 |
| Mar 31, 2022 | 122,987.00 |
| Dec 31, 2021 | 153,180.00 |
| Sep 30, 2021 | 116,248.00 |
| Jun 30, 2021 | 200,016.00 |